journal article·2020-01-03Open access

Preliminary studies of 68 Ga-NODA-USPION-BBN as a dual-modality contrast agent for use in positron emission tomography/magnetic resonance imaging

Afsaneh Lahooti, Saeed Shanehsazzadeh, Sophie Laurent

Nanotechnology· Volume 31· Issue 1

Abstract

Abstract The aim of this study was to propose a new dual-modality nanoprobe for positron emission tomography/magnetic resonance imaging (PET/MRI) for the early diagnosis of breast cancer. For synthesis of the nanoprobe, polyethylene glycol-coated ultra-small superparamagnetic iron-oxide nanoparticles (USPION) armed with NODA-GA chelate and grafted with bombesin (BBN) were radiolabeled with 68 Ga. After characterization, in vitro studies to evaluate the cell binding affinity of the nanoprobe were done by performing Perl’s Prussian blue cell staining and MRI imaging. Finally, for in vivo studies, magnetic resonance images were taken in SCID mice bearing breast cancer tumor pre- and post-injection, and a multimodal nanoScan PET/computed tomography was used to perform preclinical imaging of the radiolabeled nanoparticles. Afterwards, a biodistribution study was done on sacrificed mice. The results showed that the highest r 1 and r 2 values were measured for USPIONs at 20 and 60 MHz, respectively. From the in vitro studies, the optical density of the cells after incubation increased with the increase of the iron concentration and the duration of incubation. However, the T 2 values decreased when the iron concentration increased. Furthermore, from in vivo studies, the T 2 and signal intensity decreased during the elapsed time post-injection in the tumor area. In this study, the in vitro studies showed that the affinity of cancer cells to nanoprobe increases meaningfully after conjugation with BBN, and also by increasing the duration of incubation and the iron concentration. Meanwhile, the in vivo results confirmed that the blood clearance of the nanoprobe happened during the first 120 min post-injection of the radiolabeled nanoprobe and also confirmed the targeting ability of that to a gastrin-releasing peptide receptor positive tumor.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (44)

Show source-provided references
1. PET/MR in breast cancer10.1053/j.semnuclmed.2015.03.003 ↗
2. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence10.3310/hta14500 ↗
3. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program10.1634/theoncologist.12-1-20 ↗
4. Non-invasive sensitive brain tumor detection using dual-modality bioimaging nanoprobe10.1088/1361-6528/ab0e9c ↗
6. Synthesis and characterization of bombesin-superparamagnetic iron oxide nanoparticles as a targeted contrast agent for imaging of breast cancer using MRI10.1088/0957-4484/26/7/075101 ↗
7. Development of a novel drug targeting delivery system for cervical cancer therapy10.1088/1361-6528/aaf3f8 ↗
8. Targeting B16 tumors in vivo with peptide-conjugated gold nanoparticles10.1088/0957-4484/26/28/285101 ↗
9. Tumor imaging and targeting potential of an Hsp70-derived 14-mer peptide10.1371/journal.pone.0105344 ↗
10. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation
11. Metabolically stabilized (68)Ga-NOTA-bombesin for PET imaging of prostate cancer and influence of protease inhibitor phosphoramidon10.1021/acs.molpharmaceut.5b00970 ↗
12. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours10.1007/s00259-004-1476-2 ↗
13. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers10.1016/S0167-0115(00)00114-2 ↗
14. PEGylated superparamagnetic iron oxide nanoparticles labeled with 68Ga as a PET/MRI contrast agent: a biodistribution study10.1007/s10967-016-5058-0 ↗
15. Nano delivery systems10.1142/10309 ↗
16. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer10.1158/0008-5472.CAN-04-3921 ↗
17. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect10.1016/j.addr.2010.04.009 ↗
18. Design strategies of hybrid metallic nanoparticles for theragnostic applications10.1088/0957-4484/24/43/432002 ↗
19. New carboxysilane-coated iron oxide nanoparticles for nonspecific cell labelling10.1002/cmmi.1552 ↗
20. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting10.1016/S0065-2571(00)00013-3 ↗
21. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles10.2967/jnumed.108.051243 ↗
22. Nanoplatforms for targeted molecular imaging in living subjects10.1002/smll.200700351 ↗
23. Multifunctional targeted therapy system based on 99 mTc/177Lu-labeled gold nanoparticles-Tat(49-57)-Lys3-bombesin internalized in nuclei of prostate cancer cells10.1002/jlcr.3087 ↗
24. Fast synthesis and bioconjugation of (68) Ga core-doped extremely small iron oxide nanoparticles for PET/MR imaging10.1002/cmmi.1681 ↗
25. Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging10.1021/bc300659k ↗
26. Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides10.1158/1078-0432.CCR-08-3145 ↗
27. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo10.1002/cmmi.1627 ↗
28. Slight temperature changes affect protein affinity and cellular uptake/toxicity of nanoparticles10.1039/c3nr32551b ↗
29. Irreversible changes in protein conformation due to interaction with superparamagnetic iron oxide nanoparticles10.1039/c0nr00733a ↗
30. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine10.1021/cr1001832 ↗
31. Protein-nanoparticle interactions: opportunities and challenges10.1021/cr100440g ↗
32. Biodistribution evaluation of 166Ho-DTPA-SPION in normal rats10.1007/s10967-015-4251-x ↗
33. Development of 177Lu-DTPA-SPIO conjugates for potential use as a dual contrast SPECT/MRI imaging agent10.1515/ract-2015-2499 ↗
34. Estimated background doses of [67Ga]-DTPA-USPIO in normal Balb/c mice as a potential therapeutic agent for liver and spleen cancers10.1097/MNM.0b013e328362d2fb ↗
35. Crucial role of the protein corona for the specific targeting of nanoparticles10.2217/nnm.14.69 ↗
36. Protein corona significantly reduces active targeting yield10.1039/c3cc37307j ↗
37. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface10.1038/nnano.2012.237 ↗
38. Preclinical study on GRPR-targeted (68)Ga-probes for PET imaging of prostate cancer10.1021/acs.bioconjchem.6b00279 ↗
39. Theranostic MUC-1 aptamer targeted gold coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging and photothermal therapy of colon cancer10.1016/j.colsurfb.2016.02.058 ↗
40. Effect of PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) under magnetic field on amyloid beta fibrillation process10.1016/j.msec.2015.10.026 ↗
41. Dual nano-sized contrast agents in PET/MRI: a systematic review10.1002/cmmi.1719 ↗
42. Effect of coating thickness of iron oxide nanoparticles on their relaxivity in the MRI
43. Chemical control of superparamagnetic properties of magnesium and cobalt spinel ferrite nanoparticles through atomic level magnetic couplings10.1021/ja000784g ↗
44. Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity10.1002/jmri.21194 ↗